Investigation Report on China Phosphocreatine Market, 2010-2019
The global epidemic trend shows that cardiovascular disease has become one of the serious threats to human health whose incidence and death rate has exceeded that of malignant tumor and leapt to the first. According to the World Health Organization (WHO), about 17 million people die of cardia-cerebrovascular disease, among which 50% die of acute myocardial infarction and cerebral infarction each year in the world. Phosphocreatine, developed by Alfa Wassermann in 1997, has the largest market share compared with other cardiovascular drugs.
According to CRI’s survey, phosphocreatine develops fast after entering China with annual sales value rising from less than CNY 30 million in 2005 to CNY 1.37 billion in 2014 and CAGR during the period of 2005-2014 reaching up to 53.7%. Phosphocreatine enjoys a vast demand in China. Beijing Lifeshine Pharmaceutical Co., Ltd, Haikou Qili Pharmaceutical Co., Ltd, Hebei Tiancheng Pharmaceutical Co., Ltd, Harbin Bolai Pharmaceutical Co., Ltd and Jilin Yinglian Biopharmaceutical Co., Ltd all occupy certain shares of the market, among which Jilin Yinglian Biopharmaceutical Co., Ltd has the largest market share of over 40% with sales value in 2014 reaching up to CNY 560 million. However, Alfa Wassermann (Italy), the original developer of phosphocreatine, had a market share less than 3% in China in 2014.
As Chinese people’s living standards improve and the population ages, the incidence of cardiovascular will keep increasing and the market size of phosphocreatine in China will keep expanding too.
Readers can get at least the following information through this report:
market share of manufacturers of phosphocreatine in Chinese market
price of phosphocreatine in Chinese market
major manufacturers of phosphocreatine in China
share of different dosage forms of phosphocreatine in Chinese market
market outlook of phosphocreatine in China
The author suggests the following groups of people purchase this report:
manufacturers of drugs for cardiovascular disease
investors/ research institutions interested in Chinese medicine market
any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed